PMID- 34139370
OWN - NLM
STAT- MEDLINE
DCOM- 20210819
LR  - 20220819
IS  - 1878-3511 (Electronic)
IS  - 1201-9712 (Linking)
VI  - 108
DP  - 2021 Jul
TI  - Situational analysis of 10 countries with a high burden of drug-resistant 
      tuberculosis 2 years post-UNHLM declaration: progress and setbacks in a changing 
      landscape.
PG  - 557-567
LID - S1201-9712(21)00511-7 [pii]
LID - 10.1016/j.ijid.2021.06.022 [doi]
AB  - OBJECTIVES: Globally, drug-resistant tuberculosis (DR-TB) is the leading cause of 
      death globally related to antimicrobial resistance, affecting 500,000 emergent 
      cases annually. In 2018, the first United Nations High-Level Meeting (UNHLM) on 
      tuberculosis declared DR-TB a global public health priority. Bold country targets 
      were established for 2018-2022. This study reviews the DR-TB situation in 2018, 
      and the UNHLM target accomplishments in 10 high-burden countries (HBCs). METHODS: 
      An ecological descriptive analysis of the top 10 DR-TB HBCs (Bangladesh, China, 
      India, Indonesia, Myanmar, Nigeria, Pakistan, Philippines, Russian Federation, 
      and South Africa), which share 70% of the global DR-TB burden, was undertaken, 
      complemented by a cascade-of-care analysis and a survey gathering additional 
      information on key advances and setbacks 2 years after the UNHLM declaration. 
      RESULTS: Most countries are showing historic advances and are on track for the 
      2018 and 2019 targets. However, according to the cascade-of-care, none of the 
      countries are capable of providing effective care for 50% of the estimated 
      patients. Increasing levels of fluoroquinolone resistance and access to timely 
      susceptibility testing can jeopardize ongoing adoption of shorter, all-oral 
      treatment regimens. The programmatic management of DR-TB in children remains 
      minimal. Achievements for 2020 and beyond may be affected significantly by the 
      coronavirus disease 2019 (COVID-19) pandemic. CONCLUSION: Triggered by the 
      COVID-19 pandemic, there is a global risk of recoil in DR-TB care with long-term 
      consequences in terms of deaths, suffering and wider transmission. Investment to 
      support DR-TB services is more important now than ever to meet the aspirations of 
      the UNHLM declaration.
CI  - Copyright (c) 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.
FAU - Monedero-Recuero, Ignacio
AU  - Monedero-Recuero I
AD  - Unitat d'Atencio Territorial a la Cronicitat i Complexitat Garraf, Institut 
      Catala de la Salut, Departament de Salut, Generalitat de Catalunya, Barcelona, 
      Spain; TB-HIV Department, International Union against Tuberculosis and Lung 
      Disease, Paris, France. Electronic address: imonedero@theunion.org.
FAU - Gegia, Medea
AU  - Gegia M
AD  - Prevention, Diagnosis, Treatment, Care and Innovation Unit, Global TB Programme, 
      World Health Organization, Geneva, Switzerland.
FAU - Wares, Douglas Fraser
AU  - Wares DF
AD  - KNCV Tuberculosis Foundation, The Hague, The Netherlands.
FAU - Chadha, Sarabjit S
AU  - Chadha SS
AD  - Foundation for Innovative New Diagnostics (FIND), New Dehli, India.
FAU - Mirzayev, Fuad
AU  - Mirzayev F
AD  - Prevention, Diagnosis, Treatment, Care and Innovation Unit, Global TB Programme, 
      World Health Organization, Geneva, Switzerland.
LA  - eng
GR  - 001/WHO_/World Health Organization/International
PT  - Journal Article
DEP - 20210615
PL  - Canada
TA  - Int J Infect Dis
JT  - International journal of infectious diseases : IJID : official publication of the 
      International Society for Infectious Diseases
JID - 9610933
RN  - 0 (Antitubercular Agents)
SB  - IM
MH  - Antitubercular Agents/pharmacology/therapeutic use
MH  - *COVID-19
MH  - Child
MH  - Humans
MH  - Pandemics
MH  - SARS-CoV-2
MH  - *Tuberculosis/drug therapy/epidemiology
MH  - *Tuberculosis, Multidrug-Resistant/drug therapy/epidemiology
MH  - United Nations
OTO - NOTNLM
OT  - Antimicrobial resistance
OT  - COVID-19
OT  - DR-TB
OT  - High-burden countries
OT  - Multi-drug-resistant tuberculosis
OT  - Tuberculosis
OT  - UNHLM
EDAT- 2021/06/18 06:00
MHDA- 2021/08/20 06:00
CRDT- 2021/06/17 20:14
PHST- 2021/04/15 00:00 [received]
PHST- 2021/06/03 00:00 [revised]
PHST- 2021/06/10 00:00 [accepted]
PHST- 2021/06/18 06:00 [pubmed]
PHST- 2021/08/20 06:00 [medline]
PHST- 2021/06/17 20:14 [entrez]
AID - S1201-9712(21)00511-7 [pii]
AID - 10.1016/j.ijid.2021.06.022 [doi]
PST - ppublish
SO  - Int J Infect Dis. 2021 Jul;108:557-567. doi: 10.1016/j.ijid.2021.06.022. Epub 
      2021 Jun 15.